Revolution Medicines has zeroed in on Iambic Therapeutics’ AI drug discovery platform, striking a multi-year technology and research collaboration that gives Iambic the chance to earn up to $25 mil | ...

Two veteran biotech investors have reunited to form a new venture capital firm focusing on autoimmune diseases. Steven St. | ...